We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App





Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021 (Photo courtesy of Diagnostica Stago)
Image: Diagnostica Stago Highlights Max Generation Family of Coagulation Analyzers at MEDLAB Middle East 2021 (Photo courtesy of Diagnostica Stago)
Diagnostica Stago (Asnières-sur-Seine, France), which develops and markets automated systems for blood analysis, highlighted its Max Generation family of coagulation analyzers at MEDLAB Middle East 2021.

On display at the event was the STA R Max 3, a versatile analyzer that will adapt to any type of laboratory set-up, for an equivalent performance whether used alone or integrated into an automated track. It is supported by a range of reagents offering a comprehensive menu of routine and specialized tests, ensuring effective TAT (turnaround time) management. Like its predecessor, the STA R Max 3 has an EPC module for checking sample integrity that controls fill volumes of all types of tubes and detects haemolysed, icteric and lipemic samples to ensure quality results. It requires no additional plasma volume and does not affect throughput.

The company also presented the STA Compact Max 3 which offers significant performance improvements and includes the EPC (expert pre-analytical check) module. This EPC module controls fill volumes of all types of tubes and detects haemolysed, icteric and lipemic samples, allowing the STA Compact Max 3 to check sample integrity to ensure quality results. It requires no additional plasma volume and does not affect throughput. In addition, the company highlighted the STA Satellite Max which builds on the proven strengths of the Max Generation, offering new functionalities and a user-friendly interface, making it the ideal solution for Haemostasis testing in low-volume labs. The STA Satellite Max is a Haemostasis analyzer designed specifically for “satellite” labs looking for a device that meets their needs while guaranteeing results as reliable as those obtained in large specialized laboratories.

At this year’s MEDLAB Middle East, the company showcased the STA R Max 3, a versatile analyzer that will adapt to any type of laboratory set-up, for an equivalent performance whether used alone or integrated into an automated track. It is supported by a range of reagents offering a comprehensive menu of routine and specialized tests, ensuring effective TAT (turnaround time) management.

Related Links:
Diagnostica Stago

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Toxoplasma Rapid Test
Toxo IgG/IgM Rapid Test Kit
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.